Lilly Revenue Guidance Rises Along With Diabetes, Obesity Investments

Oral GLP-1, Injectable GGG Agonists Moving Into Phase III

 
• By Mandy Jackson
Lilly Corporate Center Indianapolis
Lilly will launch four products in 2023 and may gain a weight loss indication for Mounjaro • Source: Shutterstock

More from Business

More from Scrip